Loading clinical trials...
Loading clinical trials...
Multicenter, Open-label, 52 Week, Dose-escalation Study of SP 420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias
Conditions
Interventions
SP-420
Locations
4
Canada
University of Toronto- University Health Network
Toronto, Canada
American University of Beirut Medical Center
Beirut, Lebanon
Siriraj Hospital
Bangkok, Thailand
Ege University Hospital
Izmir, Turkey (Türkiye)
Start Date
August 1, 2020
Primary Completion Date
September 1, 2022
Completion Date
January 1, 2023
Last Updated
October 5, 2020
NCT06647979
NCT03653338
NCT06772766
NCT06606886
NCT05762510
NCT06328764
Lead Sponsor
Abfero Pharmaceuticals, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions